{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:20:28Z","timestamp":1789842028290,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autologous stem cell transplantation (ASCT) is the standard treatment of primary refractory or relapsed Hodgkin-lymphoma, which can provide a cure rate of about 50%. The aim of our study was to analyze the data of 126 HL patients undergoing AHSCT in Hungary between 01\/01\/2016 and 31\/12\/2020. We assessed the progression-free and overall survival, the prognostic role of PET\/CT performed before transplantation and effect of brentuximab vedotin (BV) treatment on survival outcomes. The median follow-up time from AHSCT was 39 (1\u201376) months. The 5-year OS comparing PET- and PET\u2009+\u2009patients was 90% v. 74% (<jats:italic>p<\/jats:italic>\u2009=\u20090.039), and 5-year PFS was 74% v. 40% (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). There was no difference in either OS or PFS compared to those who did not receive BV before AHSCT. We compared BV treatments based on their indication (BV only after AHSCT as maintenance therapy, BV before and after AHSCT as maintenance treatment, BV only before AHSCT, no BV treatment). There was statistically significant difference in the 5-year PFS based on the inication of BV therapy. Recovery rates of our R\/R HL patient population, who underwent AHSCT, improved significantly. Our positive results can be attributed to the PET\/CT directed, response-adapted treatment approach, and the widespread use of BV.<\/jats:p>","DOI":"10.1007\/s00277-023-05354-8","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T09:02:22Z","timestamp":1688979742000},"page":"2555-2563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era \u2014 real-world data from Hungary"],"prefix":"10.1007","volume":"102","author":[{"given":"Kata","family":"Husi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rox\u00e1na","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3 Imre","family":"Pincz\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"F\u00f6lde\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Szomor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Gopcsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-9997","authenticated-orcid":false,"given":"Zs\u00f3fia","family":"Milt\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"issue":"14","key":"5354_CR1","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","volume":"22","author":"G Bonadonna","year":"2004","unstructured":"Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results. J Clin Oncol 22(14):2835\u20132841","journal-title":"J Clin Oncol"},{"key":"5354_CR2","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","volume":"27","author":"A Engert","year":"2009","unstructured":"Engert A, Diehl V, Franklin J, Lohri A, D\u00f6rken B, Ludwig WD et al (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548\u20134554","journal-title":"J Clin Oncol"},{"issue":"10","key":"5354_CR3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","volume":"12","author":"NS Majhail","year":"2006","unstructured":"Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A et al (2006) Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant 12(10):1065\u20131072","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"5354_CR4","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdf228","volume":"13","author":"P Bierman","year":"2002","unstructured":"Bierman P, Lynch J, Bociek R, Whalen V, Kessinger A, Vose J et al (2002) The international prognostic factors project score for advanced Hodgkin\u2019s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 13(9):1370\u20131377","journal-title":"Ann Oncol"},{"issue":"12","key":"5354_CR5","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","volume":"19","author":"T Hahn","year":"2013","unstructured":"Hahn T, McCarthy PL, Carreras J, Zhang M-J, Lazarus HM, Laport GG et al (2013) Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 19(12):1740\u20131744","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"5354_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A, Arranz R, Caballero M, Vidal M et al (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol 16(4):625\u2013633","journal-title":"Ann Oncol"},{"key":"5354_CR7","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 359:2065\u20132071","journal-title":"Lancet"},{"key":"5354_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/bjh.16201","volume":"188","author":"P Kaloyannidis","year":"2019","unstructured":"Kaloyannidis P, Hertzberg M, Webb K, Zomas A, Schrover R, Hurst M et al (2019) Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. Br J Haematol 188:540\u2013549","journal-title":"Br J Haematol"},{"key":"5354_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bmt.1704214","volume":"32","author":"T Kewalramani","year":"2003","unstructured":"Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J et al (2003) Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin\u2019s disease or aggressive non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 32:673\u2013679","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"5354_CR10","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","volume":"116","author":"AJ Moskowitz","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD et al (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116(23):4934\u20134937","journal-title":"Blood"},{"issue":"6","key":"5354_CR11","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","volume":"28","author":"PJ Br\u00f6ckelmann","year":"2017","unstructured":"Br\u00f6ckelmann PJ, M\u00fcller H, Casasnovas O, Hutchings M, von Tresckow B, J\u00fcrgens M et al (2017) Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol 28(6):1352\u20131358","journal-title":"Ann Oncol"},{"issue":"25","key":"5354_CR12","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J et al (2018) Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 132(25):2639\u20132642","journal-title":"Blood"},{"issue":"6","key":"5354_CR13","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","volume":"8","author":"DJ Straus","year":"2021","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Connors JM, Alekseev S, Ill\u00e9s \u00c1, Picardi M et al (2021) Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 8(6):e410\u2013e421","journal-title":"Lancet Haematol"},{"issue":"10","key":"5354_CR14","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s00277-020-04204-1","volume":"99","author":"LI Pincz\u00e9s","year":"2020","unstructured":"Pincz\u00e9s LI, Szab\u00f3 R, Ill\u00e9s \u00c1, F\u00f6lde\u00e1k D, Piukovics K, Szomor \u00c1 et al (2020) Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma. Ann Hematol 99(10):2385\u20132392","journal-title":"Ann Hematol"},{"issue":"21","key":"5354_CR15","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA et al (2016) Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496","journal-title":"Blood"},{"issue":"3","key":"5354_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA et al (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97(3):616\u2013623","journal-title":"Blood"},{"issue":"9980","key":"5354_CR17","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385(9980):1853\u20131862","journal-title":"Lancet"},{"key":"5354_CR18","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119:1665\u20131670","journal-title":"Blood"},{"key":"5354_CR19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","volume":"148","author":"CH Moskowitz","year":"2010","unstructured":"Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J et al (2010) High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 148:890\u2013897","journal-title":"Br J Haematol"},{"key":"5354_CR20","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","volume":"17","author":"JP Smeltzer","year":"2011","unstructured":"Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F (2011) Abboud CNet al: Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 17:1646\u20131652","journal-title":"Biol Blood Marrow Transplant"},{"issue":"28","key":"5354_CR21","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.21.01552","volume":"39","author":"NA Bartlett","year":"2021","unstructured":"Bartlett NA (2021) optimizing second-line therapy for Hodgkin lymphoma: a work in progress. J Clin Oncol 39(28):3097\u20133103","journal-title":"J Clin Oncol"},{"key":"5354_CR22","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30:2183\u20132189","journal-title":"J Clin Oncol"},{"issue":"3","key":"5354_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jtct.2021.12.005","volume":"28","author":"O Veilleux","year":"2022","unstructured":"Veilleux O, Claveau JS, Alaoui H, Roy J, Ahmad I, Delisle JS et al (2022) Real-world outcomes of autologous and allogeneic hematopoietic stem cell transplantation for relapsed\/refractory Hodgkin lymphoma in the era of novel therapies: a Canadian perspective. Transplant Cell Ther 28(3):145\u2013151","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"5354_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/hon.2897","volume":"39","author":"OM Akay","year":"2021","unstructured":"Akay OM, Ozbalak M, Pehlivan M, Yildiz B, Uzay A, Yigenoglu TN et al (2021) Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: multicenter retrospective study. Hematol Oncol 39(4):498\u2013505","journal-title":"Hematol Oncol"},{"issue":"7","key":"5354_CR25","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3324\/haematol.2021.279564","volume":"107","author":"A Marouf","year":"2022","unstructured":"Marouf A, Cottereau AS, Kanoun S, Deschamps P, Meignan M, Franchi P et al (2022) Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica 107(7):1681\u20131686","journal-title":"Haematologica"},{"key":"5354_CR26","doi-asserted-by":"crossref","unstructured":"Chung S, White J, Toze CL, Sutherland HJ, Sanford D, Anula Rodrigo J, Nevill TJ, Narayanan S, Nantel SH, Kuchenbauer F, Hay KA, Forrest DL, Abou Mourad Y, Song K, Power M (2021) Autologous stem cell transplant outcome in classic Hodgkin lymphoma patients in the era of post-transplant brentuximab vedotin consolidation (abstract #3935).\u00a0Blood 138(Supplement 1):3935","DOI":"10.1182\/blood-2021-154492"},{"key":"5354_CR27","doi-asserted-by":"crossref","unstructured":"Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, Frank MJ, Johnston LJ, Miklos DB, Muffly L, Negrin RS, Rezvani AR, Shiraz P, Shizuru JA, Weng WK, Binkley MS, Hoppe RT, Advani RH, Arai S (2023) Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood 141(22):2727\u20132737","DOI":"10.1182\/blood.2022018827"},{"issue":"4","key":"5354_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/10428194.2021.2002322","volume":"63","author":"H Shah","year":"2022","unstructured":"Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Ramchandren R, Kim S, Deol A (2022) Improved post-ASCT survival of relapsed\/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leuk Lymphoma 63(4):813\u2013820","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5354_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.2939","volume":"40","author":"F Massaro","year":"2022","unstructured":"Massaro F, Pavone V, Stefani PM, Botto B, Pulsoni A, Patti C et al (2022) Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: a Fondazione Italiana Linfomi real-life experience. Hematol Oncol 40(1):31\u201339","journal-title":"Hematol Oncol"},{"issue":"2","key":"5354_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-022-05011-6","volume":"102","author":"C Mart\u00ednez","year":"2023","unstructured":"Mart\u00ednez C, de Haro ME, Romero S, Guti\u00e9rrez A, Domingo-Dom\u00e8nech E, Gonz\u00e1lez-Rodr\u00edguez AP et al (2023) Impact of pre- and\/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma. Ann Hematol 102(2):429\u2013437","journal-title":"Ann Hematol"},{"issue":"2","key":"5354_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00277-019-03900-x","volume":"99","author":"M Roerden","year":"2020","unstructured":"Roerden M, S\u00f6kler M, Kanz L, Bethge W, Vogel W, Walz JS (2020) Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience. Ann Hematol 99(2):265\u2013276","journal-title":"Ann Hematol"},{"issue":"10","key":"5354_CR32","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1080\/10428194.2021.1927016","volume":"62","author":"B Fakhri","year":"2021","unstructured":"Fakhri B, Yilmaz E, Gao F, Ambinder RF, Jones R, Bartlett NL, Cashen A, Wagner-Johnston N (2021) Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. Leuk Lymphoma 62(10):2408\u20132415","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"5354_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjh.15566","volume":"184","author":"PJ Br\u00f6ckelmann","year":"2019","unstructured":"Br\u00f6ckelmann PJ, McMullen S, Wilson JB, Mueller K, Goring S, Stamatoullas A, Zagadailov E, Gautam A, Huebner D, Dalal M, Illidge T (2019) Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol 184(2):202\u2013214","journal-title":"Br J Haematol"},{"issue":"9","key":"5354_CR34","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1080\/10428194.2017.1421762","volume":"59","author":"GP Collins","year":"2018","unstructured":"Collins GP, Rueda A, Salles G, von Tresckow B, Zaja F (2018) Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. Leuk Lymphoma 59(9):2113\u20132120. https:\/\/doi.org\/10.1080\/10428194.2017.1421762","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"5354_CR35","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1080\/10428194.2020.1783443","volume":"61","author":"N Khan","year":"2020","unstructured":"Khan N, Feliciano J, M\u00fcller K, He M, Tao R, Korol E, Dalal M, Rebeira M, Matasar M (2020) Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment. Leuk Lymphoma 61(11):2630\u20132637","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"5354_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11899-014-0213-6","volume":"9","author":"BD Cheson","year":"2014","unstructured":"Cheson BD (2014) Which Hodgkin\u2019s patients in the Unites States should be treated with BEACOPP? Curr Hematol Malig Rep 9(3):222\u2013226. https:\/\/doi.org\/10.1007\/s11899-014-0213-6","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05354-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05354-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05354-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:10:19Z","timestamp":1692706219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05354-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["5354"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05354-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}